Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Investing Activities (2016 - 2026)

Spyre Therapeutics' Cash from Investing Activities history spans 11 years, with the latest figure at -$247.4 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 45.07% year-over-year to -$247.4 million; the TTM value through Dec 2025 reached -$143.5 million, up 59.39%, while the annual FY2025 figure was -$143.5 million, 59.39% up from the prior year.
  • Cash from Investing Activities reached -$247.4 million in Q4 2025 per SYRE's latest filing, down from $25.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $79.0 million in Q2 2025 to a low of -$247.4 million in Q4 2025.
  • Average Cash from Investing Activities over 5 years is -$28.5 million, with a median of $6.3 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: soared 801.33% in 2023, then crashed 1882.81% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $9.7 million in 2021, then soared by 44.88% to $14.0 million in 2022, then plummeted by 351.94% to -$35.3 million in 2023, then crashed by 383.51% to -$170.5 million in 2024, then tumbled by 45.07% to -$247.4 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Cash from Investing Activities are -$247.4 million (Q4 2025), $25.0 million (Q3 2025), and $79.0 million (Q2 2025).